JAMES AMARA: Open Payments
NPI 1114671880 · GAITHERSBURG, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,174 in 44 payments from 16 companies in 2025. Trend: 2023 $23 · 2024 $931 · 2025 $1,174
Food & beverage: $1,174
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $156 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $154 |
| Vifor Pharma, Inc. | 4 | $107 |
| Mallinckrodt Hospital Products Inc. | 3 | $106 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $97 |
| Novartis Pharmaceuticals Corporation | 3 | $95 |
| Calliditas Therapeutics US Inc. | 4 | $89 |
| Amgen Inc. | 3 | $79 |
| AstraZeneca Pharmaceuticals LP | 3 | $64 |
| AKEBIA THERAPEUTICS INC | 2 | $51 |
Products named: JARDIANCE, Wegovy, Veltassa, ACTHAR, Kerendia, Fabhalta, TARPEYO, KRYSTEXXA.
Industry payments across MD — which companies pay providers there.
